Mom paralyzed after Botox-like injections ‘poisoned' her body: ‘Worst decision I've ever made'
Amanda Wolaver, 33, had been getting routine anti-wrinkle injections for 10 years with 'no issues' until a top-up left her with 'severe' headaches.
She went to the hospital the next day after waking up 'unable to move,' but a CT scan revealed 'nothing was wrong.'
9 Amanda Wolaver (right), 33, had been getting routine anti-wrinkle injections for 10 years with 'no issues' until a touch-up left her with 'severe' headaches.
Amanda Wolaver / SWNS
Over 16 months, her symptoms worsened – she became housebound for four months and everyday tasks like showering and doing her make-up became a struggle – and an MRI revealed that she even suffered from TIA strokes.
After $30,000 in tests later, a neurologist finally diagnosed Amanda with iatrogenic botulism.
The rare neuromuscular disease is caused by botulinum neurotoxins – the active ingredient in Botox.
Although there is no specific treatment, Amanda is 'recovering slowly' and letting time detoxify her body.
Amanda, a sales director from Goodhope, Georgia, said: 'It's almost been two years and I still don't feel normal.
9 Wolaver went to the hospital the next day after waking up 'unable to move,' but a CT scan revealed 'nothing was wrong.'
Amanda Wolaver / SWNS
'Never did I think this might happen to me.
'It was the worst decision I've ever made.
'I couldn't be the mother I wanted for my three children, Landen, 16, Braxton, 11, and Havyn, 5.
'As I was essentially a vegetable, unable to move, walk, drive, or do anything I love.
'But I'm grateful for the support of my husband, Josh, 39, who was there for me.
9 Over 16 months, her symptoms worsened – she became housebound for four months and everyday tasks like showering and doing her make-up became a struggle.
Amanda Wolaver / SWNS
'I want my experience to educate others about botulinum toxins.
'I learned the cost of beauty the hard way.'
Amanda paid $700 to have 104 units of Dysport – a Botox alternative she had never used before – injected into her forehead, crow's feet, and eleven lines in August 2023.
'I began developing this horrible migraine and thought if I slept it off, it would go away,' she said.
'However, when I woke up the next day, I couldn't function or string sentences together.'
9 An MRI revealed that Wolaver even suffered from TIA strokes.
Amanda Wolaver / SWNS
Botox and Dysport are neurotoxins that block muscle contractions to rid wrinkles, and both derive from botulinum toxin.
Amanda visited the hospital and was told it was 'nothing to do with the injections.'
'They told me that it was probably just a severe migraine,' she said.
'But soon, my body felt like the floor was being ripped out from underneath me and that I'd collapse.
'My dizziness became so severe that I had to take Xanax to knock me out to sleep.
'I thought I was slowly dying.'
9 After numerous of testing, a neurologist finally diagnosed Amanda with iatrogenic botulism.
Amanda Wolaver / SWNS
Amanda visited doctors multiple times to find a cause and underwent a heart monitor implant and spinal tap surgeries.
'They thought I had MS at one point and an autoimmune disorder,' she added.
'I underwent around 10 to 15 different MRIs, CTs and multiple procedures.
'I felt like a lab rat.'
Four months after her injections, a head and neck MR also revealed that the mom suffered from multiple TIA strokes.
9 Amanda, a sales director, said, 'It's almost been two years and I still don't feel normal.'
Amanda Wolaver / SWNS
'That knocked me back,' she said.
'To be told I had suffered from multiple small strokes in my brain made me think that this would eventually kill me.'
Her joint pain left her struggling to formulate sentences.
'My life was essentially ruined,' Amanda said.
9 'To be told I had suffered from multiple small strokes in my brain made me think that this would eventually kill me,' she continued.
Amanda Wolaver / SWNS
'I lost friends and couldn't hang out with my family, as loud noises and strong smells would trigger my dizziness.
'So I couldn't even cook my kids' dinner or clean the house.'
But it wasn't until she discovered a forum of people who had suffered Botox poisoning that it 'all came together.'
In March 2025, she was diagnosed with iatrogenic botulism after doctors pinned the timing and correlation of her symptoms to her Dysport injections.
9 'I've cut out caffeine, soda, and even had my breast implants taken out in April to allow my body to detoxify itself,' she continued.
Amanda Wolaver / SWNS
'It was a bittersweet moment,' she said.
'But there is no cure and no promise that I will be 100 per cent back to normal.'
Six months later, Amanda still suffers daily with lasting effects.
She said: 'I still get the occasional dizziness and I have changed my diet completely to make sure nothing bad is going in me.
9 'But now I want to create more awareness about the dangers of botulinum neurotoxins,' Wolaver said.
Amanda Wolaver / SWNS
'I've cut out caffeine, soda, and even had my breast implants taken out in April to allow my body to detoxify itself.
'I don't care about my wrinkles at all now, and I'm getting more active and able to do more things with my family.
'But now I want to create more awareness about the dangers of botulinum neurotoxins.
'Hopefully, I can help prevent this from happening to others.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
a day ago
- Newsweek
Nearly 17 Million Young Americans Could Benefit From Ozempic-like Drugs
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Nearly 17 million young Americans could be eligible for GLP-1RAs—a class of medications used to treat type 2 diabetes and obesity—including Ozempic and Wegovy. This is based on estimations from Yale School of Medicine researchers who have assessed how many adolescents and young adults in the US are eligible for the drugs and how many can realistically access them. Despite millions being eligible, one in five young adults who meet the criteria are uninsured and one-third denied having a routine place for healthcare. The researchers describe this as "a barrier to identifying, treating, and preventing cardio-kidney-metabolic diseases". The prevalence of type 2 diabetes and obesity continues to increase in youth across the country, hence the need for improved intervention. "Assuming that all individuals who were appropriate candidates for these medications could receive them after shared-decision making with their clinician, we could see substantial progress made in treating and preventing obesity-related diseases in US youth, such as dyslipidemia and hypertension," paper author Ashwin K. Chetty told Newsweek. This, he explained, "could lead to the prevention of severe complications of obesity into adulthood, such as strokes and heart attacks." Hand holding Ozempic-like injection pens on dark background. Hand holding Ozempic-like injection pens on dark said the GLP-1RA eligibility criteria they used covered indications for semaglutide (Ozempic, Rybelsus and Wegovy), liraglutide (Saxenda and Victoza), Bydureon BCise (exenatide), Trulicity (dulaglutide) and tirzepatide (Zepbound and Mounjaro). While some medications contain the same ingredient under a different brand name, the drugs are licensed in different ways. In the U.S., Ozempic, for example, is approved for use in people with type 2 diabetes, while Wegovy is approved for those with obesity or who are overweight and have related health problems. Wegovy and Ozempic mimic a hormone called glucagon-like peptide-1—hence 'GLP-1'—which targets areas of the brain that regulate appetite. "Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are approved to treat pediatric obesity and T2D, and a small but growing number of adolescents and young adults receive GLP-1RAs, which are largely covered through private insurance or Medicaid," the researchers wrote. "Insurance status, access to care and clinical profile of the broader population of youth eligible for GLP-1RAs are unclear but important for policy development. We characterized demographic, clinical, and socioeconomic characteristics of US adolescents and young adults eligible for any GLP-1RA." To inform the estimations, the cross-sectional study pooled publicly available data from the National Health and Nutrition Examination Survey (NHANES) January 2017–March 2020 and August 2021–August 2023. They included US adolescents aged 12–17 and young adults aged 18–25 who met U.S. Food and Drug Administration criteria for GLP-1RA treatment. Over-the-shoulder view of a person in bed checking a smartphone. Over-the-shoulder view of a person in bed checking a adolescents, GLP-1RA indications included type 2 diabetes or obesity defined either as BMI in the 95th percentile or higher for age and sex or body weight greater than 60kg and BMI corresponding to 30 for adults by international cutoffs. For young adults, GLP-1RA indications included type 2 diabetes, obesity (a BMI greater than 30) or a BMI of 27 or higher with a weight-related condition (dyslipidemia, hypertension, cardiovascular disease, or type 2 diabetes). The sample included 572 adolescents and 590 young adults eligible for GLP-1RA treatment, representing an estimated 5.8 million adolescents and 11.1 million young adults. Adolescents eligible for the drugs included 40.3 percent insured by Medicaid, 40.5 percent privately insured and 7.2 percent uninsured. Eligible young adults included 20.8 percent insured by Medicaid, 49 percent privately insured and 19.4 percent uninsured. While 92.2 percent of adolescents reported having a routine place for healthcare, 68.1 percent of young adults reported the same, according to the study. Among both groups, cardio-kidney-metabolic risk factors (dyslipidemia, impaired kidney function, hypertension and prediabetes) were prevalent. "Of note, some indications for young adults were fully encompassed by other indications and were not analyzed separately," said Chetty. For example, the indication of type 2 diabetes may include having also a cardiovascular disease. The analysis also did not include people aged 10–11 years with type 2 diabetes as there were too few participants in their sample in that age group with the condition. "While Medicare is not allowed to cover anti-obesity medications that are indicated only for obesity, Medicaid can cover anti-obesity medications, though only a fraction of state Medicaid programs do," said Chetty. The researchers say their findings indicate broad Medicaid coverage could increase access to GLP-1RAs for a large portion of U.S. youth who may benefit from them. "This could look like state-level formulary changes that include anti-obesity medications or federal policy changes that foster coverage for these therapies," said Chetty. "Beyond expanding insurance coverage, improving access also involves ensuring these individuals have access to general healthcare and clinician appointments, which we show in this study is a particularly significant concern for young adults." Why are we seeing rising rates of metabolic diseases in America's youth? Paper author and pediatric nephrologist Dr. James Nugent told Newsweek: "Changes in lifestyle behaviors and structural factors like increased screen time, decreased physical activity, poor sleep, and consumption of ultra-processed foods and sugar-sweetened beverages are important contributors to obesity in youth. "The COVID-19 pandemic has further accelerated the rise in obesity due to its effect on these lifestyle behaviors. Chronic stress, food insecurity, poverty, and adverse childhood experiences are also strongly associated with obesity in youth. Additionally, in utero exposure to maternal obesity and diabetes are risk factors for obesity and type 2 diabetes in childhood." The authors said study limitations include self-reported data subject to recall bias and potential misclassification of the type of diabetes. They also flagged GLP-1RAs should be considered alongside intensive health behavior and lifestyle treatment (and surgery where applicable). And while expanded insurance coverage may substantially increase access, uninsurance and lack of routine care are barriers to this therapy. How can we ensure young people receive holistic care too? "Improving access to comprehensive obesity treatment will involve ensuring that individuals receive access to healthcare with regular follow-ups and support to engage in health behavior and lifestyle treatment, such as specific programs tailored to providing intensive health behavior and lifestyle treatment," said Chetty. "As Dr. Mona Sharifi, a co-author of this paper, has shown, intensive health behavior and lifestyle treatment programs can be cost-effective but inadequate funding is the main barrier to implementing and sustaining these programs." What's next? "Given the size and clinical characteristics of the U.S. youth population eligible for GLP-1RAs, there should be greater discussion of how to improve access to GLP-1RAs and other anti-obesity interventions among this population." Do you have a tip on a health story that Newsweek should be covering? Do you have a question about GLP-1 drugs? Let us know via health@ Reference Chetty, A. K., Sharifi, M., & Nugent, J. T. (2025). Glucagon-like peptide-1 receptor agonist eligibility among US adolescents and young adults. JAMA Pediatrics.
New York Post
a day ago
- New York Post
New study reveals when most Americans fall asleep — you'll never guess the time
Is there a 'prime' bedtime? A new study found the average American falls asleep at 11:18 p.m. A new survey of 2,000 general population Americans explored respondents' nighttime routines and sleep habits — digging into their bedtimes. Advertisement The results found that the average respondent begins their nighttime routine at 10:15 p.m., taking 21 minutes to get ready for bed, on average — meaning respondents are then tucked into bed by 10:36 p.m. But it takes about forty minutes before they actually fall asleep, as results revealed the average American doesn't drift off until about a quarter past 11 o'clock. 5 A new survey of 2,000 general population Americans explored respondents' nighttime routines and sleep habits — digging into their bedtimes. New Africa – Conducted by Talker Research on behalf of Avocado Green Mattress, the survey found respondents have three mornings per week when they wake up wishing they went to bed earlier the night before. Advertisement For those who end up staying awake later than planned, respondents said they're kept up because of chores and other things they need to take care of (29%). A fifth said they stay up late because night is their favorite time of the day (21%). Others said they don't want to go to sleep and 'fast forward' to the next workday (15%) — or that it's the only time they have during the week to connect with their partner (13%). 5 The new study found the average American falls asleep at 11:18 p.m. SWNS Advertisement The survey also looked at how respondents sleep — or don't sleep — with their partner. Of respondents who share a bed with their significant other (46% of the sample), only half (49%) sleep better due to having their partner asleep next to them. On the other hand, one in seven (14%) of these respondents sleep worse, largely due to their partner's snoring (63%). 5 One in seven of these respondents sleeps worse with a partner, largely due to their partner's snoring. SWNS Advertisement Their partner waking them up during the night (tossing/turning, getting up to use the bathroom, etc.) (52%), generally having different nighttime routines (26%), and sleeping at different temperatures (24%) also contributed to poorer sleep when sharing a bed. 'For many, falling asleep and staying asleep is difficult,' said Laura Scott, director of brand marketing at Avocado Green Mattress. 'And perfectly controlling your bedtime or wind-down routine isn't always possible, since life, and sometimes other people, often get in the way. That's why having a cozy, personalized, and supportive sleep environment is so vital for a good night's rest.' With back-to-school season quickly approaching, the survey also asked parents how they anticipate this return to the classroom will impact their sleep. 5 Half of these respondents said they'll need to wake up earlier, while a quarter said they'll be going to sleep later — as they need to make lunches in the evening, help their kids with homework, etc. SWNS Parents of school-aged children (27% of the sample) said, largely, they'll get less sleep when their child goes back to school. Half (53%) of these respondents said they'll need to wake up earlier (to help get their kids ready for school, drive them to school, etc.), while a quarter said they'll be going to sleep later — as they need to make lunches in the evening, help their kids with homework, etc. And one in 10 (11%) won't sleep as well, as they have more to worry about with their child returning to school. 5 The results found that the average respondent begins their nighttime routine at 10:15 p.m., taking 21 minutes to get ready for bed, on average. Gorodenkoff – Advertisement 'Parents with kids in school can have an even harder time getting all the sleep they need, since they're making time for homework, packing lunches and making meals, driving here and there, and trying to spend quality time with their kids,' said Scott. 'With so much going on during back-to-school season, ensuring they can get a full, restful night of sleep is more important than ever.' Survey methodology: Talker Research surveyed 2,000 general population Americans; the survey was commissioned by Avocado Green Mattress and administered and conducted online by Talker Research between June 23–27, 2025.
Cosmopolitan
a day ago
- Cosmopolitan
Evolysse Hyaluronic Acid Filler Review
It's not every day a new injectable hits the beauty market, so when I first heard about Evolysse, a new type of filler from Evolus (the makers of Jeuveau, a popular type of Botox), my ears immediately perked then my skin perked up, itching to give it a try. Yes, Evolysse is a filler. The dreaded f-word. But it promises to lead the way in rebranding the way social media has conditioned us to view filler in recent months (that it's bad, unnatural, and that it will leave your face looking puffy if overdone in just the slightest) thanks to a new technology that preserves the molecular structure of hyaluronic acid so it looks smooth and natural once injected. Intrigued? I was too—and was fortunate enough to get an early sneak peek of the newest FDA-approved injectable to see how it compares to the tried-and-true injectables currently on the market. I'm here to give my honest thoughts after trying it, and help set the record straight on where this injectable fits into your cosmetic treatment routine. Evolysse is a hyaluronic acid injectable. Hyaluronic acid is a molecule that's naturally occurring in our bodies that, when injected underneath the skin, can smooth out imperfections, add volume to areas of the face, and augment features such as the lips, chin, and jawline. You know how your hyaluronic acid serum makes your skin all plump, bouncy, and firm? When injected properly, hyaluronic fillers basically create that same effect but for the long term. Hyaluronic acid fillers have been around since the early aughts, but Evolysse is the first real technological innovation in the space in the last decade, says Julie K. Karen, MD, a board-certified dermatologist in New York, NY. "It's a new group of hyaluronic acid fillers that seeks to restore volume and smooth out the lower face in a very natural and smooth way because of the innovative technology by which they're developed,' explains Dr. Karen. Said innovative technology is called Cold-X Technology. It's what sets Evolysse apart from other hyaluronic acid-injectables on the market, and it helps protect the natural structure of the hyaluronic acid molecule. I'm going to get a little sciencey here, but the gist is that hyaluronic acid molecules are sensitive to warmer temperatures when manufactured for aesthetic use, though all current ones on the market are produced in this manner. When hyaluronic acid-injectables are made at very warm temperatures, it 'denatures the hyaluronic acid,' effectively causing it to break down into shorter fragments, which are then crosslinked to reconnect them for use. 'By processing the Evolysse line at cold, near-freezing temperatures, they preserve the natural structure of hyaluronic acid. This leads to a more natural-looking result, mimicking the actual existence of hyaluronic acid in the skin,' says Dr. Karen. This process also leads to more natural tissue integration and less swelling when the product is injected into the skin. Right now, Evolysse is FDA-approved to smooth dynamic smile lines and laugh lines in the lower face, though, depending on your provider's expertise, it can be injected off-label into other areas to volumize, smooth, or augment. Currently, the Evolysse line has two different types of filler in the U.S. market: Form and Smooth. 'Evolysse Smooth is softer and more pliable, making it suitable for more superficial lines like those around the mouth, like perioral lines, marionette lines, nasolabial folds,' says Connie Yang, MD, a board-certified dermatologist in New York, NY. 'I have injected Smooth in the lips and seen a beautiful, soft result,' says Dr. Yang. Evolysse Form, on the other hand, is firmer, more robust, and gel-like, making it 'suitable for deeper folds and areas needing more volume (like cheeks, jawline, etc.). It provides more structure and contour, which is great for areas that need more volume restoration and support,' she further explains. This all being said, Dr. Yang says the family of injectables 'are quite versatile and can be used at different depths to address a wide variety of concerns on the face.' Aside from the fact that it smooths dynamic smile lines and laugh lines, augments, and restores volume to areas of the face, Evolysse doesn't cause the lumps and bumps that can potentially form post-injection. 'One of the adverse effects of hyaluronic acid fillers is sometimes delayed onset of nodules, the little lumps, bumps, or granulomas around where the filler is placed,' explains Dr. Karen. By using Cold-X Technology and maintaining the natural form of hyaluronic acid by not having to crosslink it as much, 'they are finding both in the initial pivotal study, and then in practice, there is basically a nonexistent rate of nodules. That's not to say it can't happen, but in their initial study, no delayed onset nodules formed,' Dr. Karen adds. As of now, according to that same study, Evolysse is shown to last for one year. It's important to note that the length of the study lasted only for 12 months, and that it's been reported that fillers can remain detectable in the face years longer than initially thought, so it's reasonable to infer that Evolysse lasts just as long as other hyaluronic acid-based injectables on the market in the long term. Anyone experiencing volume loss, particularly around the lower face, and who wants a natural look is a great candidate. Dr. Karen says both Smooth and Form are great for a highly mobile area, such as the mouth (you're chewing, talking, smiling, etc), because of how natural and delicate the product is. 'If you put something that is too lumpy or clumpy in that area, it may not give you the best result,' she says. Dr. Karen adds that there's really no one who isn't a good candidate, unless someone has major volume loss where their end-game aesthetics goals are not realistic from the use of injectables. As a beauty editor and self-proclaimed aesthetics guinea pig, I wanted to try Evolysse to fill in some areas of slight volume loss around my mouth that were bugging me. I visited Dr. Karen's office for my Evolysse treatment. After having numbing cream applied to my areas of concern in my lower face and sitting with it for about 10 minutes, Dr. Karen assessed my face, choosing to use Evolysse Form on me. She injected a little bit of Evolysse Form between my upper lip and cheek, the nasolabial fold, and the melolabial fold, or what people call the marionette. She also placed a little in the pre-jowl sulcus, which is that slight divot that people get at the lateral aspect of their chin, along the jawline. Thanks to the numbing cream, the experience was only very mildly uncomfortable. The whole thing took less than thirty minutes, and I saw the results of the product immediately. Though very subtle, the skin around my lower face looked smoother and slightly plumper. The immediate results are what Dr. Yang loves about the injectable. 'What's unique about Evolysse is that you can treat to correction, meaning what you see after injection is about what you can expect in the long run. With Cold-X Technology, these fillers do not swell as much as other HAs on the market, which can be a good thing depending on your treatment goals." Depending on your location, provider, and number of syringes needed, the cost may vary, but the price of Evolysse is comparable to other brands of hyaluronic acid-injectables. You can expect to pay around $900 to $1,500 for a syringe, but even this range may vary. For reference, Dr. Karen does not usually inject more than a syringe or two at a time during an appointment. While I certainly love the results from my Evolysse appointment and find them to be super natural, it ultimately does not look like I've had filler, which is arguably the whole point. Provided you go to an experienced injector, you Evolysse can definitely refresh your face without making you look overfilled or puffy. I also loved that the effects were instant—so when I left my appointment, I immediately felt good about my results. All in all, Evolysse is another great option to choose from if you're interested in fillers. Taryn is a beauty writer and editor in digital media with more than 10 years of experience. She has covered the newest and most innovative skincare and beauty products, aesthetic treatments, and plastic surgery trends. Her stories touch on everything from the best products to treat hyperpigmentation to why fat grafting is the better alternative to filler. In addition to Cosmopolitan, she currently contributes to Allure, InStyle, PS (formerly POPSUGAR), Marie Claire, The Zoe Report, and Bustle. In addition to her writing, Taryn directs, produces, and writes short films that have appeared at numerous film festivals around the country. Whenever she has a free moment, you can find her hopping around New York City with her Maltese pup, Bryn, and probably daydreaming about being at the beach. Follow her on Instagram for the latest.
